Homepage Marquee showing individuals with SMA and potential of SPINRAZA Image of Ian aged 36 years old with later-onset (type 3) SMA playing guitar
DISCOVER THE BENEFITS OFSPINRAZA® (nusinersen)
See the potential benefits Review the safety profile

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.

7500+ pediatric and adult patients with spinal muscular atrophy (SMA) have been treated with SPINRAZA worldwide.1*

*Based on commercial patients, early access patients, and clinical trial participants as of March 2019.

Find a treatment center near you

Use this Locator Tool to help find a treatment center near you that might be able to administer SPINRAZA.
 

Getting started with SPINRAZA

Once you and your patient have decided to begin treatment, submit a Start Form to enroll your patient in Biogen support services.

How does SPINRAZA work?

Watch the MOA video to learn how SPINRAZA increases the production of full-length survival motor neuron (SMN) protein.

Depending on your method of procurement, the Start Form may be used as a prescription.

The SPINRAZA clinical trials included >325 patients with SMA, ranging from ages 3 days to 16 years at first dose.1

Clinical trial results

Get a closer look at the study results across a broad range of individuals with SMA.

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.
 

Available resources for you and your patients

PATIENT MOA VIDEO

Help them learn about the MOA from Emma, a patient treated with SPINRAZA.

SMA360°™

Biogen’s SMA360° support program provides services for patients and their families that address nonmedical barriers to access.

REIMBURSEMENT

A comprehensive guide to reimbursement considerations for SPINRAZA.
 

Stay connected

Sign up to receive the latest news, support information, and upcoming events.

Enter a valid email address

 

Reference

1. Data on file. Biogen, Cambridge, MA.